Y. Imaeda

发表

Discovery of potent Mcl-1/Bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteins.

Yuta Tanaka, T. Kawamoto, T. Ishikawa, 2013, Journal of medicinal chemistry.

Discovery of piperazinylimidazo[1,2-a]pyridines as novel S4 binding elements for orally active factor Xa inhibitors.

Toshimasa Tanaka, Y. Imaeda, Mamoru Tobisu, 2008, Bioorganic & medicinal chemistry.

Discovery of sulfonylalkylamides: A new class of orally active factor Xa inhibitors.

Toshimasa Tanaka, Y. Imaeda, F. Itoh, 2008, Bioorganic & medicinal chemistry.

Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands.

M. Naito, Ryokichi Koyama, N. Cho, 2017, Journal of medicinal chemistry.

Discovery of a B-Cell Lymphoma 6 Protein-Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach.

H. Oki, Kotaro Sakamoto, G. Snell, 2017, Journal of medicinal chemistry.

Discovery of an Irreversible and Cell-Active BCL6 Inhibitor Selectively Targeting Cys53 Located at the Protein-Protein Interaction Interface.

Kotaro Sakamoto, Ikuo Miyahisa, S. Sogabe, 2018, Biochemistry.

Identification of a selective DDX3X inhibitor with newly developed quantitative high-throughput RNA helicase assays.

Masahiro Ito, S. Aparicio, T. Kawamoto, 2020, Biochemical and biophysical research communications.

Structure-based design of a new series of N-(piperidin-3-yl)pyrimidine-5-carboxamides as renin inhibitors.

C. Behnke, G. Snell, M. Tawada, 2016, Bioorganic & medicinal chemistry.

Development of protein degradation inducers of oncogenic BCR‐ABL protein by conjugation of ABL kinase inhibitors and IAP ligands

M. Naito, Tomoya Sameshima, N. Cho, 2017, Cancer science.

Discovery of imidazo[1,5-c]imidazol-3-ones: weakly basic, orally active factor Xa inhibitors.

Toshimasa Tanaka, Y. Imaeda, Mamoru Tobisu, 2008, Journal of medicinal chemistry.

Antithrombotic and Anticoagulant Profiles of TAK-442, a Novel Factor Xa Inhibitor, in a Rabbit Model of Venous Thrombosis

Y. Imaeda, N. Konishi, K. Hiroe, 2010, Journal of cardiovascular pharmacology.

Discovery of a tetrahydropyrimidin-2(1H)-one derivative (TAK-442) as a potent, selective, and orally active factor Xa inhibitor.

K. Aertgeerts, Y. Imaeda, N. Konishi, 2009, Journal of medicinal chemistry.

Discovery and Characterization of a Eukaryotic Initiation Factor 4A-3-Selective Inhibitor That Suppresses Nonsense-Mediated mRNA Decay.

Masahiro Ito, S. Aparicio, H. Oki, 2017, ACS chemical biology.

Bifunctional ligands allow deliberate extrinsic reprogramming of the glucocorticoid receptor.

J. Iñiguez-Lluhí, A. Mapp, Jonas W Højfeldt, 2014, Molecular endocrinology.

Novel benzimidazole derivatives selectively inhibit endothelial cell growth and suppress angiogenesis in vitro and in vivo.

Y. Imaeda, M. Kusaka, K. Kubo, 2002, Cancer letters.

Discovery of Novel 5-(Piperazine-1-carbonyl)pyridin-2(1H)-one Derivatives as Orally eIF4A3-Selective Inhibitors.

K. Fukuda, Y. Imaeda, Y. Kosugi, 2017, ACS medicinal chemistry letters.

Discovery of Novel 1,4-Diacylpiperazines as Selective and Cell-Active eIF4A3 Inhibitors.

Masahiro Ito, S. Aparicio, T. Kawamoto, 2017, Journal of medicinal chemistry.

Discovery of selective ATP-competitive eIF4A3 inhibitors.

Masahiro Ito, S. Aparicio, T. Kawamoto, 2017, Bioorganic & medicinal chemistry.

TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma

K. Saikatendu, C. Arrowsmith, M. Schapira, 2018, Oncotarget.

Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation

M. Naito, Ryokichi Koyama, Tomoya Sameshima, 2018, The Journal of Biological Chemistry.

In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs)*

M. Naito, Ryokichi Koyama, Mika Teratani, 2017, The Journal of Biological Chemistry.

Discovery of a novel B-cell lymphoma 6 (BCL6)-corepressor interaction inhibitor by utilizing structure-based drug design.

Terufumi Takagi, Kotaro Sakamoto, G. Snell, 2017, Bioorganic & medicinal chemistry.

Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors.

S. Aparicio, G. Morin, H. Kokubo, 2018, Journal of medicinal chemistry.

Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor

C. Behnke, G. Snell, Y. Imaeda, 2016, ACS medicinal chemistry letters.

Toward the antibody-catalyzed chemiluminescence. Design and synthesis of hapten.

J. Oda, M. Sawa, H. Kondo, 1998, Bioorganic & medicinal chemistry letters.

Discovery of benzimidazole derivatives as orally active renin inhibitors: Optimization of 3,5-disubstituted piperidine to improve pharmacokinetic profile.

C. Behnke, G. Snell, Koji Watanabe, 2018, Bioorganic & medicinal chemistry.

Discovery of high-affinity BCL6-binding peptide and its structure-activity relationship.

Kotaro Sakamoto, S. Sogabe, Y. Imaeda, 2017, Biochemical and biophysical research communications.

A model of antimycin A binding based on structure-activity studies of synthetic antimycin A analogues.

H. Iwamura, H. Miyoshi, N. Tokutake, 1995, Biochimica et biophysica acta.

Novel approach of fragment-based lead discovery applied to renin inhibitors.

H. Oki, Toshimasa Tanaka, C. Behnke, 2016, Bioorganic & medicinal chemistry.